A Multi center study of the Bruton's Tyrosine Kinase (BTK) inhibitor, Ibrutinib in combination with MEDI4736
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pharmacyclics, Inc.
Start Date
October 1, 2015
End Date
February 22, 2018
Administered By
Duke Cancer Institute
Awarded By
Pharmacyclics, Inc.
Start Date
October 1, 2015
End Date
February 22, 2018